Drugs and Products
Drug and product records organize approved obesity treatments and credible development-stage assets within the broader industry landscape. Each record should connect brand names, active ingredients, developers, manufacturers, commercial partners, mechanisms, dosage forms, routes, indications, markets, and regulatory history where reliable sourcing supports the detail.
This area is not a treatment guide or product recommendation surface. Its purpose is to help readers understand how products and pipeline assets relate to companies, active ingredients, mechanisms, clinical programs, and market structure.
Future drug and product pages should preserve jurisdiction, date, status, and source context for changing information such as approvals, label changes, safety communications, availability, shortages, launch markets, pricing, and reimbursement.
This is a starting reference snapshot for US obesity-treatment products, not treatment guidance. Status wording is US-centered and should be read with the linked source context.
For product-to-company research, weight loss drug manufacturers and commercial partners separates associated company, sponsor, labeler, manufacturer, distributor, and commercial partner wording so product records do not overstate physical manufacturing or current ownership roles.
Wegovy is Novo Nordisk’s semaglutide product in the US obesity-treatment market. Its full product record separates injection and tablet scope, adult and pediatric populations, cardiovascular and MASH indications, clinical programs, and regulatory milestones.
Sources: Wegovy product record, current DailyMed label
Zepbound is Eli Lilly’s tirzepatide product for long-term weight reduction and maintenance in a defined US adult population and for moderate-to-severe obstructive sleep apnea in adults with obesity. Its full product record separates those indications from Mounjaro, the related tirzepatide diabetes product, while connecting presentations, the SURMOUNT program, commercial channels, and regulatory milestones.
Sources: Zepbound product record, current DailyMed label
Saxenda
Section titled “Saxenda”Saxenda is Novo Nordisk’s liraglutide product for chronic weight management. It is an earlier obesity-market product in the GLP-1 receptor agonist class and is connected to Victoza, the related liraglutide diabetes product.
Source: DailyMed label search
Qsymia
Section titled “Qsymia”Qsymia is an oral phentermine/topiramate extended-release product used in the US chronic weight-management market. It represents a fixed-dose combination category outside the newer incretin-based obesity products.
Source: DailyMed label search
Contrave
Section titled “Contrave”Contrave is an oral naltrexone/bupropion extended-release product used in the US chronic weight-management market. Its ownership and commercialization context should be handled as dated company-level information when more detailed records are added.
Source: DailyMed label search
Xenical
Section titled “Xenical”Xenical is the prescription orlistat product in the US obesity-management market. It belongs to the lipase inhibitor category, which is mechanistically distinct from incretin-based products such as Wegovy, Zepbound, and Saxenda.
Source: DailyMed label search
Alli is the lower-dose nonprescription orlistat product for weight loss in adults in the US market. It is useful for industry mapping because it connects obesity-related product coverage to over-the-counter distribution rather than only prescription channels.
Source: DailyMed label search